INCYIncyte CorporationRunning, no new patients
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Pancreatic Cancer · Colorectal Cancer (CRC) · Breast Cancer · Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 10 (final count)
- Started
- Nov 30, 2016
- Main results expected
- Sep 30, 2027
- Fully finished
- Sep 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Frequency and types of adverse events and serious adverse events
Measured over: Maximum duration of every 2 months (maximum duration of 1 month for subjects receiving regorafenib) from enrollment through 30-37 days after end of treatment up to 24 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02955940 · record last updated 2026-08-17 · checked 2026-11-09 15:47 UTC